{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T15:10:43Z","timestamp":1793718643964,"version":"4.6.1"},"reference-count":69,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nuclear Medicine"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1053\/j.semnuclmed.2023.09.002","type":"journal-article","created":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T08:57:11Z","timestamp":1699001831000},"page":"163-170","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"title":["Advances in PET Imaging of the CXCR4 Receptor: [68Ga]Ga-PentixaFor"],"prefix":"10.1053","volume":"54","author":[{"given":"Liza","family":"Lindenberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Ahlman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Mena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1086-8826","authenticated-orcid":false,"given":"Peter","family":"Choyke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.semnuclmed.2023.09.002_bib0001","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.2174\/1381612043452640","article-title":"Chemokines and their receptors as therapeutic targets: The role of the SDF-1\/CXCR4 axis","volume":"10","author":"Juarez","year":"2004","journal-title":"Curr Pharm Des"},{"key":"10.1053\/j.semnuclmed.2023.09.002_bib0002","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.591386","article-title":"CXCR4 and CXCR7 Signaling Pathways: A focus on the cross-talk between cancer cells and tumor microenvironment","volume":"11","author":"Santagata","year":"2021","journal-title":"Front Oncol"},{"key":"10.1053\/j.semnuclmed.2023.09.002_bib0003","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s13578-020-00497-x","article-title":"CXCR7: A \u03b2-arrestin-biased receptor that potentiates cell migration and recruits \u03b2-arrestin2 exclusively through G\u03b2\u03b3 subunits and GRK2","volume":"10","author":"Nguyen","year":"2020","journal-title":"Cell Biosci"},{"key":"10.1053\/j.semnuclmed.2023.09.002_bib0004","doi-asserted-by":"crossref","first-page":"585","DOI":"10.3389\/fendo.2019.00585","article-title":"The Role of the CXCL12\/CXCR4\/ACKR3 axis in autoimmune diseases","volume":"10","author":"Garc\u00eda-Cuesta","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1053\/j.semnuclmed.2023.09.002_bib0005","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1126\/science.8356453","article-title":"Genotypic and phenotypic characterization of HIV-1 patients with primary infection","volume":"261","author":"Zhu","year":"1993","journal-title":"Science"},{"key":"10.1053\/j.semnuclmed.2023.09.002_bib0006","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1080\/07853890.2021.1974084","article-title":"Role and implications of the CXCL12\/CXCR4\/CXCR7 axis in atherosclerosis: Still a debate","volume":"53","author":"Murad","year":"2021","journal-title":"Ann Med"},{"key":"10.1053\/j.semnuclmed.2023.09.002_bib0007","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s12149-018-1290-8","article-title":"CXCR4-directed theranostics in oncology and inflammation","volume":"32","author":"Kircher","year":"2018","journal-title":"Ann Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.09.002_bib0008","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.2967\/jnumed.111.098798","article-title":"PET of CXCR4 expression by a 68Ga-labeled highly specific targeted contrast agent","volume":"52","author":"Gourni","year":"2011","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.09.002_bib0009","doi-asserted-by":"crossref","first-page":"7648","DOI":"10.1021\/jm2009716","article-title":"Design, synthesis, and functionalization of dimeric peptides targeting chemokine receptor CXCR4","volume":"54","author":"Demmer","year":"2011","journal-title":"J Med Chem"},{"key":"10.1053\/j.semnuclmed.2023.09.002_bib0010","doi-asserted-by":"crossref","first-page":"618","DOI":"10.7150\/thno.11251","article-title":"Disclosing the CXCR4 expression in lymphoproliferative diseases by targeted molecular imaging","volume":"5","author":"Wester","year":"2015","journal-title":"Theranostics"},{"key":"10.1053\/j.semnuclmed.2023.09.002_bib0011","doi-asserted-by":"crossref","first-page":"499","DOI":"10.2967\/jnumed.116.179663","article-title":"Imaging the cytokine receptor CXCR4 in atherosclerotic plaques with the radiotracer 68Ga-pentixafor for PET","volume":"58","author":"Hyafil","year":"2017","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.09.002_bib0012","doi-asserted-by":"crossref","first-page":"477","DOI":"10.15252\/emmm.201404698","article-title":"In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma","volume":"7","author":"Philipp-Abbrederis","year":"2015","journal-title":"EMBO Mole Med"},{"key":"10.1053\/j.semnuclmed.2023.09.002_bib0013","doi-asserted-by":"crossref","first-page":"369","DOI":"10.7150\/thno.21397","article-title":"Dual targeting of acute leukemia and supporting niche by CXCR4-directed theranostics","volume":"8","author":"Habringer","year":"2018","journal-title":"Theranostics"},{"key":"10.1053\/j.semnuclmed.2023.09.002_bib0014","doi-asserted-by":"crossref","first-page":"410","DOI":"10.2967\/jnumed.114.151647","article-title":"Biodistribution and radiation dosimetry for the chemokine receptor CXCR4-targeting probe 68Ga-Pentixafor","volume":"56","author":"Herrmann","year":"2015","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.09.002_bib0015","first-page":"1687","article-title":"Imaging of C-X-C motif chemokine receptor 4 expression in 690 patients with solid or hematologic neoplasms using 68Ga-PentixaFor PET","volume":"63","author":"Buck","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.09.002_bib0016","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1007\/s11307-023-01830-9","article-title":"Lymphoma-sink effect in marginal zone lymphoma based on CXCR4-targeted molecular imaging","volume":"25","author":"Kosmala","year":"2023","journal-title":"Mol Imaging Biol"},{"key":"10.1053\/j.semnuclmed.2023.09.002_bib0017","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s11307-022-01717-1","article-title":"Impact of tumor burden on normal organ distribution in patients imaged with CXCR4-Targeted [68Ga]Ga-PentixaFor PET\/CT","volume":"24","author":"Serfling","year":"2022","journal-title":"Mol Imaging Biol"},{"key":"10.1053\/j.semnuclmed.2023.09.002_bib0018","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20211272","article-title":"Imaging CXCR4 receptors expression for staging multiple myeloma by using 68 Ga-Pentixafor PET\/CT: Comparison with 18 F-FDG PET\/CT","volume":"95","author":"Shekhawat","year":"2022","journal-title":"BJR"},{"key":"10.1053\/j.semnuclmed.2023.09.002_bib0019","doi-asserted-by":"crossref","first-page":"205","DOI":"10.7150\/thno.16576","article-title":"[(68)Ga]Pentixafor-PET\/CT for imaging of chemokine receptor CXCR4 expression in multiple myeloma - Comparison to [(18)F]FDG and laboratory values","volume":"7","author":"Lapa","year":"2017","journal-title":"Theranostics"},{"key":"10.1053\/j.semnuclmed.2023.09.002_bib0020","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s00259-019-04605-z","article-title":"Chemokine receptor-4 targeted PET\/CT with (68)Ga-Pentixafor in assessment of newly diagnosed multiple myeloma: Comparison to (18)F-FDG PET\/CT","volume":"47","author":"Pan","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2023.09.002_bib0021","doi-asserted-by":"crossref","first-page":"E2333","DOI":"10.3390\/cancers12082333","article-title":"18F-FDG, 11C-Methionine, and 68Ga-Pentixafor PET\/CT in patients with smoldering multiple myeloma: imaging pattern and clinical features","volume":"12","author":"Zhou","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1053\/j.semnuclmed.2023.09.002_bib0022","doi-asserted-by":"crossref","first-page":"5986","DOI":"10.7150\/thno.75847","article-title":"Reduced splenic uptake on 68Ga-Pentixafor-PET\/CT imaging in multiple myeloma - A potential imaging biomarker for disease prognosis","volume":"12","author":"Kraus","year":"2022","journal-title":"Theranostics"},{"key":"10.1053\/j.semnuclmed.2023.09.002_bib0023","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s12149-021-01652-1","article-title":"Prognostic significance of 68Ga-Pentixafor PET\/CT in multiple myeloma recurrence: A comparison to 18F-FDG PET\/CT and laboratory results","volume":"35","author":"Kuyumcu","year":"2021","journal-title":"Ann Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.09.002_bib0024","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13550-020-00681-7","article-title":"Preliminary evidence of imaging of chemokine receptor-4-targeted PET\/CT with [68Ga]pentixafor in non-Hodgkin lymphoma: Comparison to [18F]FDG","volume":"10","author":"Pan","year":"2020","journal-title":"EJNMMI Res"},{"key":"10.1053\/j.semnuclmed.2023.09.002_bib0025","doi-asserted-by":"crossref","first-page":"567","DOI":"10.7150\/thno.48620","article-title":"CXCR4 PET imaging of mantle cell lymphoma using [68Ga]Pentixafor: Comparison with [18F]FDG-PET","volume":"11","author":"Mayerhoefer","year":"2021","journal-title":"Theranostics"},{"key":"10.1053\/j.semnuclmed.2023.09.002_bib0026","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/RLU.0000000000004638","article-title":"68Ga-Pentixafor PET\/MRI for treatment response assessment in mantle cell lymphoma: Comparison between changes in lesion CXCR4 expression on PET and lesion size and diffusivity on MRI","volume":"48","author":"Mayerhoefer","year":"2023","journal-title":"Clin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.09.002_bib0027","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.2967\/jnumed.120.257279","article-title":"Improved Primary staging of marginal-zone lymphoma by addition of CXCR4-directed PET\/CT","volume":"62","author":"Duell","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.09.002_bib0028","doi-asserted-by":"crossref","first-page":"3653","DOI":"10.7150\/thno.31032","article-title":"Prospective non-invasive evaluation of CXCR4 expression for the diagnosis of MALT lymphoma using [68Ga]Ga-Pentixafor-PET\/MRI","volume":"9","author":"Haug","year":"2019","journal-title":"Theranostics"},{"key":"10.1053\/j.semnuclmed.2023.09.002_bib0029","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1182\/blood.2021013239","article-title":"CXCR4 PET\/MRI for follow-up of gastric mucosa-associated lymphoid tissue lymphoma after first-line Helicobacter pylori eradication","volume":"139","author":"Mayerhoefer","year":"2022","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2023.09.002_bib0030","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.2967\/jnumed.119.226134","article-title":"68Ga-Pentixafor PET\/CT for imaging of chemokine receptor 4 expression in Waldenstr\u00f6m macroglobulinemia\/lymphoplasmacytic lymphoma: Comparison to 18F-FDG PET\/CT","volume":"60","author":"Luo","year":"2019","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.09.002_bib0031","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s13550-021-00852-0","article-title":"Semi-quantitative measurements of chemokine receptor 4-targeted 68Ga-pentixafor PET\/CT in response assessment of Waldenstr\u00f6m macroglobulinemia\/lymphoplasmacytic lymphoma","volume":"11","author":"Pan","year":"2021","journal-title":"EJNMMI Res"},{"key":"10.1053\/j.semnuclmed.2023.09.002_bib0032","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.2967\/jnumed.120.241703","article-title":"CXCR4-targeted PET imaging of central nervous system B-cell lymphoma","volume":"61","author":"Herhaus","year":"2020","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.09.002_bib0033","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/RLU.0000000000003404","article-title":"Assessment of central nervous system lymphoma based on CXCR4 expression in vivo using [68Ga]Pentixafor-PET\/MRI","volume":"46","author":"Starzer","year":"2021","journal-title":"Clin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.09.002_bib0034","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1007\/s11307-021-01664-3","article-title":"CXCR4-Directed PET\/CT with [68Ga]Pentixafor in central nervous system lymphoma: A comparison with [18F]FDG PET\/CT","volume":"24","author":"Chen","year":"2021","journal-title":"Mol Imaging Biol"},{"key":"10.1053\/j.semnuclmed.2023.09.002_bib0035","doi-asserted-by":"crossref","first-page":"741","DOI":"10.2967\/jnumed.115.161034","article-title":"First experience with chemokine receptor CXCR4-targeted PET imaging of patients with solid cancers","volume":"57","author":"Vag","year":"2016","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.09.002_bib0036","doi-asserted-by":"crossref","first-page":"770","DOI":"10.3389\/fonc.2019.00770","article-title":"CXCR4-directed imaging in solid tumors","volume":"9","author":"Werner","year":"2019","journal-title":"Front Oncol"},{"key":"10.1053\/j.semnuclmed.2023.09.002_bib0037","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s13550-018-0442-0","article-title":"PET imaging of chemokine receptor CXCR4 in patients with primary and recurrent breast carcinoma","volume":"8","author":"Vag","year":"2018","journal-title":"EJNMMI Res"},{"key":"10.1053\/j.semnuclmed.2023.09.002_bib0038","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1097\/RLU.0000000000004674","article-title":"Impact of CXCR4-directed PET\/CT on staging and proposed oncologic management in patients with digestive system tumors","volume":"48","author":"Weich","year":"2023","journal-title":"Clin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.09.002_bib0039","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.7150\/thno.18754","article-title":"Imaging of Chemokine receptor 4 expression in neuroendocrine tumors: A triple tracer comparative approach","volume":"7","author":"Werner","year":"2017","journal-title":"Theranostics"},{"key":"10.1053\/j.semnuclmed.2023.09.002_bib0040","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s00259-021-05196-4","article-title":"CXCR4 expression in glioblastoma tissue and the potential for PET imaging and treatment with [68Ga]Ga-Pentixafor \/[177Lu]Lu-Pentixather","volume":"49","author":"Jacobs","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2023.09.002_bib0041","doi-asserted-by":"crossref","first-page":"428","DOI":"10.7150\/thno.13986","article-title":"(68)Ga-Pentixafor-PET\/CT for imaging of chemokine receptor 4 expression in glioblastoma","volume":"6","author":"Lapa","year":"2016","journal-title":"Theranostics"},{"key":"10.1053\/j.semnuclmed.2023.09.002_bib0042","doi-asserted-by":"crossref","first-page":"9288","DOI":"10.18632\/oncotarget.7063","article-title":"[68Ga]Pentixafor-PET\/CT for imaging of chemokine receptor 4 expression in small cell lung cancer: Initial experience","volume":"7","author":"Lapa","year":"2016","journal-title":"Oncotarget"},{"key":"10.1053\/j.semnuclmed.2023.09.002_bib0043","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1007\/s00259-022-06059-2","article-title":"[68Ga]Ga-Pentixafor PET\/CT imaging for in vivo CXCR4 receptor mapping in different lung cancer histologic sub-types: Correlation with quantitative receptors\u2019 density by immunochemistry techniques","volume":"50","author":"Watts","year":"2023","journal-title":"Eur J Nucl Med Mole Imag"},{"key":"10.1053\/j.semnuclmed.2023.09.002_bib0044","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1097\/MNM.0000000000001719","article-title":"Diagnostic value of [68Ga]Ga-Pentixafor versus [18F]FDG PET\/CTs in non-small cell lung cancer: A head-to-head comparative study","volume":"44","author":"Mirshahvalad","year":"2023","journal-title":"Nucl Med Commun"},{"key":"10.1053\/j.semnuclmed.2023.09.002_bib0045","doi-asserted-by":"crossref","first-page":"96","DOI":"10.2967\/jnumed.121.262206","article-title":"68Ga-Pentixafor PET\/CT for detection of chemokine receptor CXCR4 expression in myeloproliferative neoplasms","volume":"63","author":"Kraus","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.09.002_bib0046","doi-asserted-by":"crossref","first-page":"503","DOI":"10.3389\/fonc.2019.00503","article-title":"[68Ga]-Pentixafor PET\/CT for CXCR4-mediated imaging of vestibular schwannomas","volume":"9","author":"Breun","year":"2019","journal-title":"Front Oncol"},{"key":"10.1053\/j.semnuclmed.2023.09.002_bib0047","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1158\/1078-0432.CCR-17-1756","article-title":"CXCR4 Is a potential target for diagnostic PET\/CT imaging in Barrett's dysplasia and esophageal adenocarcinoma","volume":"24","author":"Fang","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.semnuclmed.2023.09.002_bib0048","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40644-021-00391-w","article-title":"Pentixafor PET\/CT for imaging of chemokine receptor 4 expression in esophageal cancer: A first clinical approach","volume":"21","author":"Linde","year":"2021","journal-title":"Cancer Imaging"},{"key":"10.1053\/j.semnuclmed.2023.09.002_bib0049","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1097\/RLU.0000000000001435","article-title":"Investigating the chemokine receptor 4 as potential theranostic target in adrenocortical cancer patients","volume":"42","author":"Bluemel","year":"2017","journal-title":"Clin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.09.002_bib0050","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.2967\/jnumed.123.265464","article-title":"CXCR4-Directed imaging and endoradiotherapy in desmoplastic small round cell tumors","volume":"64","author":"Hartlapp","year":"2023","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.09.002_bib0051","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1161\/HYPERTENSIONAHA.117.09975","article-title":"Targeting CXCR4 (CXC Chemokine Receptor Type 4) for molecular imaging of aldosterone-producing adenoma","volume":"71","author":"Heinze","year":"2018","journal-title":"Hypertension"},{"key":"10.1053\/j.semnuclmed.2023.09.002_bib0052","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1007\/s00259-020-04722-0","article-title":"Imaging CXCR4 expression in patients with suspected primary hyperaldosteronism","volume":"47","author":"Ding","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2023.09.002_bib0053","doi-asserted-by":"crossref","first-page":"368","DOI":"10.2967\/jnumed.121.261964","article-title":"Functional characterization of adrenocortical masses in nononcologic patients using 68 Ga-Pentixafor","volume":"63","author":"Ding","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.09.002_bib0054","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1007\/s00330-022-09058-x","article-title":"Functional nodules in primary aldosteronism: Identification of CXCR4 expression with 68Ga-pentixafor PET\/CT","volume":"33","author":"Gao","year":"2023","journal-title":"Eur Radiol"},{"key":"10.1053\/j.semnuclmed.2023.09.002_bib0055","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgad421","article-title":"The value of targeting CXCR4 with 68Ga-Pentixafor PET\/CT for subtyping primary aldosteronism","author":"Zheng","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1053\/j.semnuclmed.2023.09.002_bib0056","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.55609","article-title":"Accuracy of Gallium-68 Pentixafor positron emission tomography-computed tomography for subtyping diagnosis of primary aldosteronism","volume":"6","author":"Hu","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1053\/j.semnuclmed.2023.09.002_bib0057","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1097\/RLU.0000000000004244","article-title":"Usefulness of 68 Ga-Pentixafor PET\/CT on diagnosis and management of cushing syndrome","volume":"47","author":"Ding","year":"2022","journal-title":"Clin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.09.002_bib0058","doi-asserted-by":"crossref","first-page":"266","DOI":"10.2967\/jnumed.117.196485","article-title":"Clinical molecular imaging of chemokine receptor CXCR4 expression in atherosclerotic plaque using 68Ga-Pentixafor PET: Correlation with cardiovascular risk factors and calcified plaque burden","volume":"59","author":"Weiberg","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.09.002_bib0059","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1007\/s00259-017-3831-0","article-title":"[68Ga]Pentixafor-PET\/MRI for the detection of chemokine receptor 4 expression in atherosclerotic plaques","volume":"45","author":"Li","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2023.09.002_bib0060","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1007\/s00259-019-04322-7","article-title":"[68Ga]Pentixafor PET\/MR imaging of chemokine receptor 4 expression in the human carotid artery","volume":"46","author":"Li","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2023.09.002_bib0061","doi-asserted-by":"crossref","first-page":"751","DOI":"10.2967\/jnumed.119.234484","article-title":"Imaging inflammation in atherosclerosis with CXCR4-directed 68 Ga-Pentixafor PET\/CT: Correlation with 18 F-FDG PET\/CT","volume":"61","author":"Kircher","year":"2020","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.09.002_bib0062","first-page":"1039","article-title":"Imaging inflammation in atherosclerosis with CXCR4-directed [68Ga]PentixaFor PET\/MRI-compared with [18F]FDG PET\/MRI","volume":"12","author":"Lu","year":"2022","journal-title":"Life (Basel)"},{"key":"10.1053\/j.semnuclmed.2023.09.002_bib0063","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.3390\/biom10121629","article-title":"[68Ga]Ga-Pentixafor for PET imaging of vascular expression of CXCR-4 as a marker of arterial inflammation in HIV-infected patients: A comparison with 18F[FDG] PET imaging","volume":"10","author":"Lawal","year":"2020","journal-title":"Biomolecules"},{"key":"10.1053\/j.semnuclmed.2023.09.002_bib0064","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/art.42290","article-title":"Association of (18) F-Fluorodeoxyglucose-positron emission tomography activity with angiographic progression of disease in large vessel vasculitis","volume":"75","author":"Quinn","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"10.1053\/j.semnuclmed.2023.09.002_bib0065","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.2967\/jnumed.117.193037","article-title":"Integrating MRI and Chemokine receptor CXCR4-Targeted PET for detection of leukocyte infiltration in complicated urinary tract infections after kidney transplantation","volume":"58","author":"Derlin","year":"2017","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.09.002_bib0066","doi-asserted-by":"crossref","first-page":"320","DOI":"10.2967\/jnumed.117.193854","article-title":"68Ga-Pentixafor PET\/CT imaging of chemokine receptor CXCR4 in chronic infection of the bone: First insights","volume":"59","author":"Bouter","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.09.002_bib0067","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.chest.2020.08.2043","article-title":"Clinical molecular imaging of pulmonary CXCR4 expression to predict outcome of pirfenidone treatment in idiopathic pulmonary fibrosis","volume":"159","author":"Derlin","year":"2021","journal-title":"Chest"},{"key":"10.1053\/j.semnuclmed.2023.09.002_bib0068","doi-asserted-by":"crossref","first-page":"248","DOI":"10.2967\/jnumed.115.167361","article-title":"First-in-human experience of CXCR4-Directed Endoradiotherapy with 177Lu- and 90Y-Labeled Pentixather in advanced-stage multiple myeloma with extensive intra- and extramedullary disease","volume":"57","author":"Herrmann","year":"2016","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.09.002_bib0069","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.7150\/thno.19119","article-title":"[177Lu]pentixather: Comprehensive preclinical characterization of a First CXCR4-directed endoradiotherapeutic agent","volume":"7","author":"Schottelius","year":"2017","journal-title":"Theranostics"}],"container-title":["Seminars in Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299823000806?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299823000806?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T22:43:10Z","timestamp":1757544190000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001299823000806"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":69,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S0001299823000806"],"URL":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2023.09.002","relation":{},"ISSN":["0001-2998"],"issn-type":[{"value":"0001-2998","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in PET Imaging of the CXCR4 Receptor: [68Ga]Ga-PentixaFor","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nuclear Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2023.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}